[1] [1] Hornykiewicz, O. (1982) Brain neurotransmitter changes in Parkinson’s disease. In: Marsden, C.D. and Fahn, S. Eds., Movement disorders, Butterworth Scientific, London, 41-58.
[2] Hornykiewicz, O., Kish, S., Becker, L., Farley, I. and Shannak, K. (1986) Brain neurotransmitters in dystonia musculorum deformans. New England Journal of Medicine, 315, 347-353. doi:10.1056/NEJM198608073150602
[3] Birkmayer, W. and Hornykiewicz, O. (1961) Der L-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinse. Wiener KlinischeWochenschrift, 73, 787-788.
[4] Chase, T., Engber, T. and Mouradian, M. (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology, 44, S15-S18.
[5] Elsworth, J. and Roth, R. (1997) Dopamine synthesis, uptake, metabolism and receptors: Relevance to gene therapy of Parkinson’s disease. Experimental Neurology, 144, 4-9. doi:10.1006/exnr.1996.6379
[6] Stern, M. and Freese, A. (1997) Parkinson’s disease: The case for novel treatment strategies. Experimental Neurology, 144, 2-3. doi:10.1006/exnr.1996.6378
[7] Fiancada, M., Forsayeth, J. and Bankiewicz, K. (2008) Current status of gene therapy trials for Parkinson’s disease. Experimental Neurology, 209, 51-57. doi:10.1016/j.expneurol.2007.08.009
[8] Feng, L.R. and Maquire-Zeiss, K.A. (2010) Gene therapy in Parkinson’s disease: Rationale and current status. CNC Drugs, 24, 177-192. doi:10.2165/11533740-000000000-00000
[9] Ungerstedt, U. (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiologica Scandinavica Supplements, 367, 69-93.
[10] Huotari, M., Kukkonen, K., Liikka, N., Potasev, T., Raasmaja, A. and Mannisto, P.T. (2000) Effects of histamine H3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism and Related Disorders, 6, 159-164. doi:10.1016/S1353-8020(00)00007-9
[11] Tornwall, M. and Mannisto, P.T. (1993) Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. European Journal of Pharmacology, 250, 77-84. doi:10.1016/0014-2999(93)90623-P
[12] Paxinos, G. and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
[13] Laitinen, M., Makinen, K., Manninen, H., Matsi, P., Kossila, M., Agrawal, R.S., Pakkanen, T., Luoma, J.S., Viita, H., Hartikainen, J., Alhava, E., Laakso, M. and Yla-Herttuala, S. (1998) Adenovirus-mediated Gene Transfer to Lower Limb Artery of Patients with Chronic Critical Leg Ischemia. Human Gene Therapy, 9, 1481-1486. doi:10.1089/hum.1998.9.10-1481
[14] Puumalainen, A.M., Vapalahti, M., Agrawal, R.S., Kossila, M., Laukkanen, J., Lehtolainen, P., Viita, H., Paljarvi, L., Vanninen, R. and Yla-Herttuala, S. (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Human Gene Therapy, 9, 1769-1774.
[15] McMenamin, M.M., Lantos, T., Carter, E.E., Hamilton, L., Charlton, H.M., Gonzalez, S.C. and Wood, M.J.A. (2004) Neuropathological consequences of delivering an adenoviral vector in the rat brain. Journal of Gene Medicine, 6, 740-750. doi:10.1002/jgm.564
[16] Peltekian, E., Parrish, E., Bouchard, C., Peschanski, M. and Lisovovski, F. (1997) Adenovirus-mediated gene transfer to the brain: Methodological assessment. Journal of Neuroscience Methods, 71, 77-84. doi:10.1016/S0165-0270(96)00128-8
[17] Abe, K., Setoguchi, Y., Hayashi, T. and Itoyama. (1997) Dissociative expression of adenoviral-mediated E. coli LacZ gene between ischemic and reperfused rat brains. Neuroscience Letters, 226, 53-56. doi:10.1016/S0304-3940(97)00243-7
[18] Horellou, P., Vigne, E., Castel, M.N., Barnéoud, P., Colin P., Perricaudet, M., Delaère and Mallet, J. (1994) Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson’s disease. Neuro Report, 6, 49-53. doi:10.1097/00001756-199412300-00014
[19] Cieselska, A., Mittermeyer, G., Hadaczek, P., Forsayeth, J. and Bankiewicz, S. (2011) Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Molecular Therapy, 19, 922-927. doi:10.1038/mt.2010.248
[20] Flotte, T.R., Frederickson, R.M., Lowenstein, P.R. and Mueller, C. (2011) Moving forward toward a cure for parkinson’s: neuropathology of the nigrostriatal pathway determines the location of growth factor delivery. Molecular Therapy, 19, 827-829. doi:10.1038/mt.2011.76